IO Biotech, Inc. is a biopharmaceutical company that focuses on developing innovative therapies to enhance the immune system's ability to fight cancer and other diseases. By leveraging its proprietary platform, the company aims to create novel treatment options that work by targeting tumor-associated proteins and stimulating the immune response. Their pipeline includes various candidates in clinical development, which are designed to improve patient outcomes and offer new possibilities for people facing challenging health conditions. Through its research and development efforts, IO Biotech is committed to transforming the landscape of cancer treatment and improving the quality of life for patients. Read More
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed.
